menu search

KVUE / Kenvue is a “show me story” after strong start following J&J spinoff

Kenvue is a “show me story” after strong start following J&J spinoff
UBS analysts initiated coverage of Kenvue Inc (KVUE), the recent spinoff of Johnson & Johnson (NYSE:JNJ)'s consumer brand segment, with a ‘Neutral' rating and a 12-month target price of $28 per share, saying the company is well positioned to deliver sustainable mid-single-digit organic revenue growth over the medium term. “With much of the low-hanging fruit from a valuation perspective captured following the +20% performance since IPO, we think KVUE has become more of a ‘show-me story' and the direction of the stock will depend on estimate revisions from here,” the analysts wrote. Read More
Posted: May 30 2023, 14:45
Author Name: Proactive Investors
Views: 111095

KVUE News  

Can Kenvue Be a Reliable Dividend Stock to Hold for the Long Haul?

By The Motley Fool
November 1, 2023

Can Kenvue Be a Reliable Dividend Stock to Hold for the Long Haul?

Kenvue stock pays a fairly high dividend that yields 4.4%. The company is expecting modest revenue growth of around 6% this year. more_horizontal

Kenvue Inc. (KVUE) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 28, 2023

Kenvue Inc. (KVUE) Q3 2023 Earnings Call Transcript

Kenvue Inc (NYSE:KVUE ) Q3 2023 Earnings Conference Call October 26, 2023 8:30 AM ET Company Participants Tina Romani - Head of Investor Relations Thi more_horizontal

Kenvue CEO Thibaut Mongon: We feel very good about the strength of our business model

By CNBC Television
October 26, 2023

Kenvue CEO Thibaut Mongon: We feel very good about the strength of our business model

Kenvue CEO Thibaut Mongon joins ‘Squawk on the Street' to discuss the company's latest quarter, their new products in the market, and more. more_horizontal

Kenvue shares lower amid slow start to cold and flu season

By Proactive Investors
October 26, 2023

Kenvue shares lower amid slow start to cold and flu season

Kenvue Inc's shares fell 1.7% in pre-market trading after the company posted in-line third-quarter earnings but tightened its full-year guidance after more_horizontal

Kenvue's stock slides premarket as company reports slow start to flu and cold season

By Market Watch
October 26, 2023

Kenvue's stock slides premarket as company reports slow start to flu and cold season

Kenvue Inc.'s stock KVUE, -1.25% fell 2.4% in premarket trade Thursday, after the company posted in-line third-quarter earnings but tightened its full more_horizontal

Kenvue reports higher Q3 revenue on self-care products strength

By Reuters
October 26, 2023

Kenvue reports higher Q3 revenue on self-care products strength

Kenvue on Thursday reported higher third-quarter revenue, owing to strong demand for its self-care and skincare products such as Tylenol and Neutrogen more_horizontal

Kenvue is one of few IPOs trading cheap relative to long-term value: Lido Advisors' Gina Sanchez

By CNBC Television
October 20, 2023

Kenvue is one of few IPOs trading cheap relative to long-term value: Lido Advisors' Gina Sanchez

Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss IPOs performing below their debut prices, defensive IPO names to more_horizontal

Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond

By Seeking Alpha
October 19, 2023

Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond

Kenvue Inc., a subsidiary of Johnson & Johnson, is a major player in the consumer health industry with a diverse range of products. The company succes more_horizontal


Search within

Pages Search Results: